Redeye is positive about the results from CLS’s study at Skåne University Hospital.
Redeye provides an update following Guard Therapeutics’ announcement of new encouraging results from...
Redeye comments on Truecaller ahead of its Q3 results, due on 28 October.
Redeye takes a positive stance towards Addnode’s acquisition of SolidCAD.
* Q3 sales -36% vs cons, EBIT SEK -3m vs cons 91m * Main reason is delayed deliveries, Q3 order inta...
Flexion’s shares are down more than 15% following a report by the newspaper "Affärsvärlden" about a ...
Starbreeze is entering a new phase of strategic focus, driven by an expanded content pipeline for Pa...
Redeye briefly comments on Cinclus’ announcement that the first patient has been dosed in its pivota...
Redeye shares its view on Sleep Cycle ahead of the Q3 report due on 24 October.
Redeye provides a preview of SSH’s Q3 results, set to be released on 23 October.
Redeye somewhat reduces its forecasts and Base Case in Transtema following lowered expectations on t...
Redeye briefly comments on Guard Therapeutics announcing additional encouraging data from its comple...
Redeye comments on Physitrack ahead of its Q3 results, due on 21 October (rescheduled from 31 Octobe...
Redeye leaves a comment following Alzinova’s announcement that the FDA has granted Fast Track Design...
* Q2 order book size and only one announced order in Q3 add risk * We cut EBIT by 2% in 2025-27e, ma...
In a preliminary release ahead of its full report on 24 October 2025, AVTECH announced Q3 2025 net s...
Redeye is positive about Corline’s and Kardium’s development with a new ten-year agreement, and that...
Redeye kommenterar nedläggningen av ”Project Baxter”, som vi tror var rätt beslut givet förutsättnin...
Redeye provides a short comment on IRLAB’s announcement that MSRD (Otsuka) has issued a USD4m paymen...
Redeye is optimistic after Hansa’s directed share issue tonight, which was expanded from USD60m to U...